Multiple early-phase clinical trials have investigated CD33, CD123, and CD38 as potential CAR-T targets in relapsed and refractory AML, with varying response rates and degrees of toxicity [103,105]. The gene discussed is CD38; the disease is acute myeloid leukemia.